ARS Pharmaceuticals Ownership | Who Owns ARS Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

ARS Pharmaceuticals Ownership Summary


ARS Pharmaceuticals is owned by 49.86% institutional investors, 16.82% insiders, and 33.32% retail investors. Ra capital management is the largest institutional shareholder, holding 11.04% of SPRY shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.00% of its assets in ARS Pharmaceuticals shares.

SPRY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockARS Pharmaceuticals49.86%16.82%33.32%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management10.86M11.04%$109.15M
Orbimed advisors8.29M8.43%$83.30M
Deerfield management company, l.p. (series c)7.50M7.63%$75.41M
Rubric capital management lp6.20M6.27%$72.23M
Blackrock funding, inc. /de5.09M5.15%$59.24M
Sr one capital management, lp4.01M4.06%$46.75M
Abrdn3.56M3.60%$41.43M
Vanguard group3.51M3.55%$40.88M
State street2.90M2.94%$29.10M
Alliancebernstein2.64M2.69%$26.55M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sr one capital management, lp4.01M6.62%$46.75M
Bioimpact capital1.30M2.14%$13.10M
Orbimed advisors8.29M1.96%$83.30M
Nextech invest936.73K1.60%$9.88M
Ra capital management10.86M1.34%$109.15M
Casdin capital1.60M1.34%$16.08M
Deerfield management company, l.p. (series c)7.50M1.15%$75.41M
Lisanti capital growth396.51K1.09%$4.62M
Nextech invest660.70K1.01%$6.64M
Investment management associates inc /adv311.50K1.00%$3.63M

Top Buyers

HolderShares% AssetsChange
Rubric capital management lp6.20M0.86%1.70M
Casdin capital1.60M1.34%1.60M
Ubs group2.21M0.00%1.55M
Bamco inc /ny/1.27M0.03%1.23M
Qube research1.03M0.01%1.03M

Top Sellers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)7.50M1.15%-2.22M
Adage capital partners gp---1.73M
Wellington management group llp---1.43M
Octagon capital advisors lp---1.35M
Alliancebernstein2.64M0.01%-1.18M

New Positions

HolderShares% AssetsChangeValue
Casdin capital1.60M1.34%1.60M$16.08M
Qube research1.03M0.01%1.03M$10.40M
Eversept partners, lp976.51K0.68%976.51K$9.81M
Bank of montreal /can/643.41K0.00%643.41K$7.50M
Investment management associates inc /adv311.50K1.00%311.50K$3.63M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Principal securities-17.00
True wealth design-21.00
Stephens consulting-30.00
Capital performance advisors llp-33.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025144-28.00%49,264,084-41.09%490.69%69-39.47%42-10.64%
Sep 30, 20251961.03%83,443,647-1.27%841.15%111-1.77%46-
Jun 30, 20251921.59%84,508,65610.87%851.42%11112.12%46-16.36%
Mar 31, 20251888.05%76,205,3346.92%771.44%992.06%5420.00%
Dec 31, 20241641.23%68,247,8906.54%701.61%88-14.56%4469.23%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF1.98M2.00%-10.67K
Vanguard US Total Market Shares ETF1.86M1.90%-
Vanguard Total Stock Mkt Idx Inv1.75M1.77%-
Franklin Biotechnology Discv A(acc)USD1.56M1.58%-
abrdn Healthcare Opportunities1.42M1.43%-103.33K
abrdn Healthcare Investors1.42M1.43%-
iShares Russell 2000 ETF1.42M1.43%1.42M
Baron Discovery Strategy1.07M1.09%-
Baron Discovery Institutional1.07M1.09%-
AB Small Cap Growth A1.05M1.06%-56.95K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 13, 2025Dorsey Brian Chief Operating OfficerSell$190.05K
Nov 12, 2025Chakma Justin Chief Business OfficerSell$267.36K
Nov 12, 2025Chakma Justin Chief Business OfficerSell$1.21M
Aug 21, 2025Lowenthal Richard E PRESIDENT AND CEOSell$724.35K
Aug 21, 2025Scott Kathleen D. Chief Financial OfficerSell$187.50K

Insider Transactions Trends


DateBuySell
2025 Q4-3
2025 Q3-5
2025 Q2-6
2025 Q1-5
2024 Q4-58

SPRY Ownership FAQ


Who Owns ARS Pharmaceuticals?

ARS Pharmaceuticals shareholders are primarily institutional investors at 49.86%, followed by 16.82% insiders and 33.32% retail investors. The average institutional ownership in ARS Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which ARS Pharmaceuticals falls below.

Who owns the most shares of ARS Pharmaceuticals?

ARS Pharmaceuticals’s largest shareholders are Ra capital management (10.86M shares, 11.04%), Orbimed advisors (8.29M shares, 8.43%), and Deerfield management company, l.p. (series c) (7.5M shares, 7.63%). Together, they hold 27.10% of ARS Pharmaceuticals’s total shares outstanding.

Does Blackrock own ARS Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of ARS Pharmaceuticals.

Who is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 6.62% of its assets in 4.01M ARS Pharmaceuticals shares, valued at 46.75M$.

Who is the top mutual fund holder of ARS Pharmaceuticals shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of ARS Pharmaceuticals shares, with 2.00% of its total shares outstanding invested in 1.98M ARS Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools